DxS announced the launch of its first CE-marked diagnostic kit to detect EGFR gene mutations, the company announced this week.
The TheraScreen: EGFR29 kit will help doctors select lung cancer patients suitable for treatment with tyrosine kinase inhibitor therapies, such as Roche/OSI’s Tarceva and AstraZeneca’s Iressa.
For some patients, studies show that EGFR mutations correlate with responsiveness to tyrosine kinase inhibitors. The TheraScreen: EGFR29 kit – combining allele-specific and real-time PCR technology – detects 29 of the most common somatic EGFR mutations.
“The TheraScreen kit detects mutations that are frequently missed by other methods, the most common of which is DNA sequencing,” the company said in a statement.